If You Invested in Promis Neuroscie (PMN)

ProMIS Neurosciences Inc. (Nasdaq: PMN) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibodies and vaccines that are selective for toxic misfolded protein oligomers. These oligomers are associated with the development and progression of neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA) and Parkinson’s disease (PD). The company’s common shares trade on The Nasdaq Capital Market under the symbol PMN, and ProMIS is incorporated in Ontario, Canada with offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (Canada).

According to company disclosures, ProMIS applies its proprietary target discovery engine, EpiSelect™, to identify conformational epitopes that are uniquely exposed on toxic misfolded proteins. These epitopes, described as Disease Specific Epitopes (DSEs), can then be used to generate misfolding-specific antibodies or vaccine formulations. This computational platform has been used to create multiple humanized IgG1 antibody candidates that are designed to bind selectively to disease-associated oligomeric forms of proteins while sparing normal monomers and fibrils.

Alzheimer’s disease program and PMN310

The company’s lead product candidate is PMN310, a humanized monoclonal antibody for the treatment of Alzheimer’s disease. Company materials describe PMN310 as being designed to selectively target toxic amyloid‑beta oligomers (AβO), which are believed to be a major driver of synaptic dysfunction and downstream disease pathology in AD. PMN310 is engineered to avoid binding to amyloid plaque and monomer, with the stated goal of focusing activity on toxic soluble oligomers and potentially reducing or eliminating amyloid‑related imaging abnormalities (ARIA) liability that have been associated with plaque‑binding antibodies.

ProMIS reports that PMN310 has advanced into clinical development through a Phase 1a trial (NCT06105528) and an ongoing Phase 1b trial called PRECISE‑AD (NCT06750432). PRECISE‑AD is described as a randomized, double‑blind, placebo‑controlled, multiple ascending dose study in patients with mild cognitive impairment due to AD and mild AD (Stage 3 and Stage 4). The trial is designed to evaluate safety, tolerability and pharmacokinetics of intravenous PMN310 at doses of 5, 10 and 20 mg/kg, and to assess biomarker and clinical effects. Company announcements state that PRECISE‑AD is intended to be the first study to examine a monoclonal antibody directed solely against toxic amyloid‑beta oligomers on AD‑related biomarkers and clinical outcomes, with a primary focus on safety and ARIA monitoring.

ProMIS has disclosed that PMN310 received Fast Track designation from the U.S. Food and Drug Administration in July 2025 for Alzheimer’s disease. The company has also reported that, based on available data from early cohorts in PRECISE‑AD, PMN310 has shown a favorable safety profile with no treatment‑related serious adverse events and no cases of ARIA observed to date in the reported periods. An independent Data and Safety Monitoring Board (DSMB) recommended continuation of the Phase 1b trial and escalation to the final dose cohort after reviewing safety data through Cohort 2.

Biomarker‑driven clinical trial design

Company communications emphasize a biomarker‑centric approach in PRECISE‑AD. ProMIS highlights the incorporation of plasma phosphorylated tau (pTau), including pTau217, as a central endpoint at 6 and 12 months, based on analyses suggesting that plasma pTau changes may predict later clinical outcomes in early Alzheimer’s trials. In addition to pTau, the trial is described as evaluating a panel of biomarkers such as neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), Abeta42/40 ratios and synaptic integrity markers (for example SNAP25 and neurogranin) to assess target engagement, neuronal injury and potential disease‑modifying effects.

The company states that the PRECISE‑AD study is powered to provide 95% confidence for detection of ARIA and is designed with a sample size intended to yield meaningful insight into the effects of PMN310 on biomarkers and clinical outcomes. ProMIS has communicated plans for a blinded 6‑month interim analysis and a final 12‑month top‑line analysis, both focused on safety, biomarker changes and clinical measures.

EpiSelect™ platform and pipeline beyond Alzheimer’s

Beyond PMN310, ProMIS describes a broader pipeline built on its EpiSelect™ platform. The platform is used to identify conformational epitopes uniquely exposed on toxic misfolded proteins involved in various neurodegenerative diseases. Company descriptions indicate that this approach has generated additional humanized IgG1 antibody candidates and vaccine concepts targeting other misfolded proteins.

Key disclosed pipeline programs include:

• PMN267 (ALS program): A humanized IgG1 antibody directed against toxic misfolded TDP‑43, identified as a potential therapeutic target for amyotrophic lateral sclerosis. ProMIS reports that PMN267 is ready to progress to IND‑enabling studies.
• PMN442 (Parkinson’s disease and MSA program): A humanized IgG1 antibody that the company identifies as its lead candidate for Parkinson’s disease, multiple system atrophy and other synucleinopathies. It is described as having selective binding and protective activity against pathogenic forms of alpha‑synuclein and is also reported to be ready to progress to IND‑enabling studies.
• PMN311 Aβ vaccine program: ProMIS states that it continues to advance a vaccine program in Alzheimer’s disease (PMN311) based on an oligomer‑target epitope derived from its platform, with preclinical mouse vaccination studies indicating induction of antibody responses selective for pathogenic molecular species.

In multiple disclosures, the company notes that its platform has identified specific epitopes for alpha‑synuclein toxic oligomers/soluble fibrils that drive synucleinopathies and for pathogenic TDP‑43 in ALS and FTD, and that lead candidate antibodies have been generated against these targets. The same epitope information has been translated into vaccine constructs evaluated in preclinical models.

Regulatory, corporate and capital markets context

ProMIS Neurosciences is a reporting issuer in the United States and files with the Securities and Exchange Commission under Commission File Number 001‑41429. SEC filings and company press releases confirm that its common shares are registered under Section 12(b) of the Securities Exchange Act and listed on The Nasdaq Capital Market under the symbol PMN.

In 2025, the company addressed Nasdaq’s minimum bid price requirement by obtaining shareholder approval for a share consolidation and implementing a one‑for‑twenty‑five reverse stock split of its common shares. An 8‑K filed on November 24, 2025 describes the reverse split, effective November 28, 2025, including proportional adjustments to equity incentive plans, stock options and warrants, and notes that trading on Nasdaq would continue under the PMN symbol with a new CUSIP. A subsequent 8‑K dated December 16, 2025 reports that Nasdaq notified ProMIS it had regained compliance with the $1.00 minimum bid price rule after the company’s closing bid price met or exceeded $1.00 for ten consecutive business days.

ProMIS has also disclosed capital‑raising activities and an at‑the‑market (ATM) offering program with a placement agent, as well as appointments and compensation arrangements for directors and executives through its proxy statements and Form 8‑K filings. These filings outline governance structures, special meetings of shareholders, and resolutions such as the share consolidation proposal and potential adjournment of a special meeting.

Research focus and scientific publications

Company news releases highlight peer‑reviewed publications and conference presentations related to its scientific strategy. One publication discussed by ProMIS examines the relationship between efficacy and preferential targeting of soluble amyloid‑beta aggregates, reporting that clinical efficacy across Aβ‑directed antibodies correlated with binding to toxic oligomers even in the presence of high monomer concentrations. In this analysis, PMN310 is reported to have shown high resistance to monomer competition and no detectable plaque binding in preclinical models, which the company interprets as supporting a potential for greater potency and a possible lower risk of ARIA.

Another publication described by the company analyzes plasma phosphorylated tau (pTau181 and pTau217) as a potential early predictor of clinical benefit in Alzheimer’s trials. Using summary data from several monoclonal antibody trials, the analysis found a strong correlation between 6‑month plasma pTau changes and 12‑month changes in the Clinical Dementia Rating Sum of Boxes (CDR‑SB). ProMIS cites these findings as support for its biomarker‑driven design of PRECISE‑AD, where plasma pTau is used as a central endpoint to inform early proof‑of‑concept decisions.

Position within biotechnology and neurodegeneration research

Within the broader biotechnology sector, ProMIS Neurosciences is classified in research and development in biotechnology and operates within the professional, scientific, and technical services sector. Its disclosures consistently present a focus on toxic misfolded protein oligomers as central drivers of neurodegenerative disease pathology, and on generating antibodies and vaccines that are selective for these pathogenic species. By combining a computational epitope discovery engine with clinical‑stage antibody programs, the company positions its work at the intersection of protein misfolding biology, antibody engineering and biomarker‑guided clinical trial design.

Frequently asked questions (FAQ)

The following questions and answers summarize key points drawn directly from company disclosures and regulatory filings.